Dr. Reddy’s Laboratories reported consolidated revenues of ₹335,933 million for the full financial year 2026, representing 3.2% YoY growth. The fourth quarter saw revenues of ₹75,162 million, impacted by a one-time shelf stock adjustment for its generic Lenalidomide product. Despite one-off charges, the company remains focused on strengthening its core branded businesses, improving margins through cost efficiencies, and building long-term growth in biosimilars, consumer health, and innovative products.
Financial Performance Overview
For the quarter ended March 31, 2026, Dr. Reddy’s reported revenues of ₹75,162 million. The full financial year performance reached ₹335,933 million. The company’s profitability faced pressure in Q4 due to specific one-time adjustments, including a ₹4,530 million shelf stock adjustment for Lenalidomide in the U.S. and an impairment of ₹2,277 million related to CAR-T assets and Eftilagimod Alfa.
Segment Breakdown
Global Generics remains the largest contributor, with annual revenues of ₹299,033 million. The segment saw a 3% YoY growth for the full year. Emerging Markets performed strongly, posting 23% YoY growth to reach ₹67,608 million, driven by new product launches and higher volumes. India operations grew 16% YoY, achieving ₹62,186 million in revenue, bolstered by new brand launches and favorable portfolio expansion.
Strategic Milestones and Outlook
The company achieved several key operational goals in Q4, including the successful first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution (OTC) in the U.S. and the introduction of generic Semaglutide in India. Furthermore, Dr. Reddy’s completed the integration of its Consumer Healthcare business in Nicotine Replacement Therapy (NRT). Looking ahead, the company continues to invest in complex generics, biosimilars, and innovation to drive sustainable value and margin improvements.
Dividend and Governance
The Board of Directors has recommended a final dividend of ₹8 per equity share for the financial year 2025-26, subject to shareholder approval. Additionally, the company announced the 42nd Annual General Meeting will be held on July 23, 2026. Key leadership changes were also confirmed, including the appointment of new independent directors and the elevation of Mr. Sandeep Khandelwal to Senior Management Personnel.
Source: BSE
